AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11248823 — intervention group
Group type: COMPARATOR
Intervention: Distilled water for 3 minutes
Number of subjects: 60
Study 11248823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 9893219 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (EET), 16 weeks, 3 sessions per week, progressing from 50% to 85% of maximal workload
Number of subjects: 21
Study 9893219 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), no exercise
Number of subjects: 21
Study 8671137 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated patient-held medical record summary (CHR) plus written personal health record (PHR)
Number of subjects: 364
Study 8671137 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated patient-held medical record summary (CHR) only
Number of subjects: 364
Study 8671137 — intervention group
Group type: EXPERIMENTAL
Intervention: Written personal health record (PHR) only
Number of subjects: 364
Study 8671137 — intervention group
Group type: COMPARATOR
Intervention: No personal record (Control)
Number of subjects: 364
Study 2551250 — intervention group
Group type: EXPERIMENTAL
Intervention: (2''R)-4'-0-tetrahydropyranyladriamycin (THP), vincristine (VCR), ACNU
Number of subjects: 60
Study 2551250 — intervention group
Group type: COMPARATOR
Intervention: adriamycin (ADM), vincristine (VCR), ACNU
Number of subjects: 60
Study 1257173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 10
Study 1257173 — intervention group
Group type: EXPERIMENTAL
Intervention: Food drink
Number of subjects: 10
Study 1257173 — intervention group
Group type: COMPARATOR
Intervention: Inert pill (placebo)
Number of subjects: 10
Study 1257173 — intervention group
Group type: EXPERIMENTAL
Intervention: Early drug withdrawal
Number of subjects: 10
Study 31166038 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based music intervention (HBMI)
Number of subjects: 60
Study 27865949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (JB-1)
Number of subjects: 29
Study 27865949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25995100 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 50
Study 25995100 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume exercise
Number of subjects: 50
Study 25995100 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 23594787 — intervention group
Group type: COMPARATOR
Intervention: EOC (epirubicin 50 mg/m², oxaliplatin 130 mg/m², capecitabine 1250 mg/m²)
Number of subjects: 553
Study 23594787 — intervention group
Group type: EXPERIMENTAL
Intervention: mEOC+P (epirubicin 50 mg/m², oxaliplatin 100 mg/m², capecitabine 1000 mg/m², panitumumab 9 mg/kg)
Number of subjects: 553
Study 21489291 — intervention group
Group type: COMPARATOR
Intervention: 0 Gy radiation
Number of subjects: 40
Study 21489291 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Gy radiation
Number of subjects: 40
Study 21489291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Gy radiation
Number of subjects: 40
Study 21489291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Gy radiation
Number of subjects: 40
Study 18389243 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of the proximal femur measuring red marrow area percentage
Number of subjects: 27
Study 18389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Red marrow area percentage
Number of subjects: 27
Study 18389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow hemosiderosis and duration of symptoms and serum ferritin
Number of subjects: 27
Study 17219490 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted intervention providing detailed information about CPR, MV, and advance directives
Number of subjects: 297
Study 17219490 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 297
Study 17219490 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted intervention
Number of subjects: 297
Study 12505859 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month maintenance intervention with weekly telephone contacts and monthly supervised reinforcement sessions (n = 87)
Number of subjects: 172
Study 12505859 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 85)
Number of subjects: 172
Study 10868721 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Lobe Score (FLS)
Number of subjects: 118
Study 9049568 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (25 mg zinc as sulphate)
Number of subjects: 118
Study 9049568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (800 micrograms retinol palmitate)
Number of subjects: 118
Study 9049568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg zinc as sulphate)
Number of subjects: 118
Study 9049568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch containing capsules)
Number of subjects: 118
Study 8478172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 30
Study 8478172 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 30
Study 8478172 — intervention group
Group type: COMPARATOR
Intervention: Iopentol (contrast medium)
Number of subjects: 30
Study 8478172 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol (contrast medium)
Number of subjects: 30
Study 3530768 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone withdrawal
Number of subjects: 14
Study 3530768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the first or second 6 week period)
Number of subjects: 14
Study 3530768 — intervention group
Group type: EXPERIMENTAL
Intervention: Open withholding of amrinone for another 6 weeks
Number of subjects: 14
Study 3530768 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (in 2 patients)
Number of subjects: 14
Study 30057052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage (40 min)
Number of subjects: 72
Study 30057052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage (80 min)
Number of subjects: 72
Study 30057052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ice massage)
Number of subjects: 72
Study 27594122 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 1720
Study 24968124 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoint KI3
Number of subjects: 24
Study 22686358 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioral therapy (CBT) for 12 weeks
Number of subjects: 47
Study 22686358 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 47
Study 19860985 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Ca as calcium carbonate
Number of subjects: 13
Study 19860985 — intervention group
Group type: COMPARATOR
Intervention: Absence of Ca
Number of subjects: 13
Study 19860985 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Ca
Number of subjects: 13
Study 17915969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (target daily dose, 200 mg) plus cognitive-behavior therapy (CBT)
Number of subjects: 73
Study 17915969 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cognitive-behavior therapy (CBT)
Number of subjects: 73
Study 15618102 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based (WB) modules
Number of subjects: 75
Study 15618102 — intervention group
Group type: COMPARATOR
Intervention: Paper practice guidelines
Number of subjects: 75
Study 12153602 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg daily
Number of subjects: 48
Study 12153602 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA 2 mg with 35 micro g ethinylestradiol
Number of subjects: 48
Study 12153602 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA 50 mg with 25 micro g ethinylestradiol
Number of subjects: 48
Study 12153602 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily
Number of subjects: 48
Study 10434235 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg (oral single dose)
Number of subjects: 48
Study 10434235 — intervention group
Group type: COMPARATOR
Intervention: Control group (normolipemic subjects)
Number of subjects: 48
Study 7607582 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐induced extracorporeal LDL precipitation (HELP)
Number of subjects: 30
Study 7607582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HELP treatment)
Number of subjects: 30
Study 2198908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 93
Study 2198908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 93
Study 2198908 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 93
Study 2198908 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 93
Study 2198908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 29600401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early voiding trial (4 hours post-operatively on the day of surgery)
Number of subjects: 57
Study 29600401 — intervention group
Group type: COMPARATOR
Intervention: Standard voiding trial (6 am on post-operative day 1)
Number of subjects: 57
Study 30151821 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily thereafter)
Number of subjects: 300
Study 30151821 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (200 IU/Kg daily for 30 days followed by 150 IU/kg daily thereafter)
Number of subjects: 300
Study 30151821 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 300
Study 30151821 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 300
Study 26254585 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 10 μg/kg
Number of subjects: 74
Study 26254585 — intervention group
Group type: COMPARATOR
Intervention: Atropine 15 μg/kg
Number of subjects: 74
Study 23157466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 10 mg twice daily
Number of subjects: 0
Study 21545485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg with fluconazole 200 mg
Number of subjects: 28
Study 21545485 — intervention group
Group type: COMPARATOR
Intervention: Fesoterodine 8 mg alone
Number of subjects: 28
Study 19932842 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar cautery tonsillectomy
Number of subjects: 114
Study 19932842 — intervention group
Group type: COMPARATOR
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 114
Study 16492851 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (ICB)
Number of subjects: 104
Study 16492851 — intervention group
Group type: COMPARATOR
Intervention: Humeral block (HB)
Number of subjects: 104
Study 15534127 — intervention group
Group type: EXPERIMENTAL
Intervention: ROP-randomized group
Number of subjects: 244
Study 15534127 — intervention group
Group type: COMPARATOR
Intervention: No-ROP group
Number of subjects: 244
Study 15534127 — intervention group
Group type: EXPERIMENTAL
Intervention: ROP-randomized children
Number of subjects: 244
Study 15534127 — intervention group
Group type: COMPARATOR
Intervention: No-ROP children
Number of subjects: 244
Study 15534127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sighted-randomized children
Number of subjects: 244
Study 15534127 — intervention group
Group type: COMPARATOR
Intervention: Blind/low vision children
Number of subjects: 244
Study 11006189 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg lignocaine
Number of subjects: 150
Study 11006189 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg lignocaine
Number of subjects: 150
Study 9037324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dippers (group 1) - 46 subjects
Number of subjects: 100
Study 9037324 — intervention group
Group type: COMPARATOR
Intervention: Nondippers (group 2) - 54 subjects
Number of subjects: 100
Study 8315702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 19
Study 8315702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3565792 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.5%)
Number of subjects: 24
Study 3565792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (0.8%)
Number of subjects: 24
Study 3565792 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (group III)
Number of subjects: 24
Study 3565792 — intervention group
Group type: COMPARATOR
Intervention: Halothane (0.5%) and Enflurane (0.8%)
Number of subjects: 24
Study 28890326 — intervention group
Group type: EXPERIMENTAL
Intervention: TauroLock™‐Hep500 used twice per week and TauroLock™‐U25,000 once a week
Number of subjects: 106
Study 27890482 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (a rich source of NO3‐) for 1 week
Number of subjects: 20
Study 27890482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27890482 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 20
Study 24297945 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenously, weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Number of subjects: 791
Study 24297945 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (9 MIU subcutaneously thrice weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Number of subjects: 791
Study 24297945 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus/bevacizumab
Number of subjects: 791
Study 24297945 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa/bevacizumab
Number of subjects: 791
Study 22569889 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured cuff BP in current clinical practice
Number of subjects: 225
Study 22569889 — intervention group
Group type: COMPARATOR
Intervention: Assuming perfect sphygmomanometer measurement
Number of subjects: 225
Study 22569889 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual clinical visit based on JNC 7 guideline
Number of subjects: 225
Study 22569889 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of clinic visit
Number of subjects: 225
Study 20975026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (physicians in intervention practices)
Number of subjects: 2847
Study 20975026 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians in control practices)
Number of subjects: 2847
Study 18799426 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of naltrexone
Number of subjects: 48
Study 18799426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16517306 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle reconstruction (group AD)
Number of subjects: 72
Study 16517306 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle reconstruction (group S)
Number of subjects: 72
Study 16517306 — intervention group
Group type: COMPARATOR
Intervention: Nonanatomic double-bundle reconstruction (group N-AD)
Number of subjects: 72
Study 16517306 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study 12543884 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty (plus medication if necessary)
Number of subjects: 210
Study 12543884 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 210
Study 11696071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg sustained-release melatonin 0.5 h before daytime sleep episodes
Number of subjects: 21
Study 11696071 — intervention group
Group type: COMPARATOR
Intervention: Placebo before daytime sleep episodes
Number of subjects: 21
Study 11696071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg sustained-release melatonin
Number of subjects: 21
Study 9715537 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophoresis of serum for 'M' band and Immunoelectrophoretic analysis of the serum
Number of subjects: 72
Study 9715537 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of urinary Bence Jones proteins
Number of subjects: 72
Study 9715537 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa and lambda light chain analysis
Number of subjects: 72
Study 9715537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential follow-up study
Number of subjects: 72
Study 9715537 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular approach to diagnosis of paraproteinemia
Number of subjects: 72
Study 12959304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine (6-MP)
Number of subjects: 149
Study 3107483 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal antirheumatic drug therapy
Number of subjects: 0
Study 3107483 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthesis index (EI)
Number of subjects: 0
Study 31760817 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter plus reminder call (RC)
Number of subjects: 3215
Study 31760817 — intervention group
Group type: EXPERIMENTAL
Intervention: Two letters plus educational material and a counseling call (CC)
Number of subjects: 3215
Study 31760817 — intervention group
Group type: COMPARATOR
Intervention: Reminder letter only (LO)
Number of subjects: 3215
Study 31760817 — intervention group
Group type: EXPERIMENTAL
Intervention: CC
Number of subjects: 3215
Study 31760817 — intervention group
Group type: EXPERIMENTAL
Intervention: RC
Number of subjects: 3215
Study 30714310 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 0
Study 30714310 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 28127948 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated DTC capsule (Duodart®) 0.5 mg dutasteride and 0.4 mg tamsulosin
Number of subjects: 2
Study 28127948 — intervention group
Group type: COMPARATOR
Intervention: Commercial formulation of dutasteride and tamsulosin
Number of subjects: 2
Study 26560823 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine (CHX) varnish
Number of subjects: 30
Study 26560823 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (control)
Number of subjects: 30
Study 23739024 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention practices
Number of subjects: 26005
Study 23739024 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention practices
Number of subjects: 26005
Study 23739024 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for alcohol use disorders
Number of subjects: 26005
Study 19846269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg i.v.) or Prednisone (40 mg by mouth × 2 days)
Number of subjects: 181
Study 19846269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 19267711 — intervention group
Group type: COMPARATOR
Intervention: Pio + ADA
Number of subjects: 51
Study 19267711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pio + PC
Number of subjects: 51
Study 19267711 — intervention group
Group type: COMPARATOR
Intervention: Met + ADA
Number of subjects: 51
Study 16614786 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 127
Study 16614786 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training combined with child therapy (CT)
Number of subjects: 127
Study 15378678 — intervention group
Group type: EXPERIMENTAL
Intervention: mecamylamine (15 mg; oral)
Number of subjects: 12
Study 15378678 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg, s.c.)
Number of subjects: 12
Study 15378678 — intervention group
Group type: EXPERIMENTAL
Intervention: mecamylamine (15 mg) + scopolamine (0.4 mg)
Number of subjects: 12
Study 15378678 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 11520711 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice a day
Number of subjects: 232
Study 11520711 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 232
Study 11520711 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice a day (in Australasian population)
Number of subjects: 232
Study 11520711 — intervention group
Group type: COMPARATOR
Intervention: placebo (in Australasian population)
Number of subjects: 232
Study 9039862 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor fungus concentrations in asthmatic children
Number of subjects: 92
Study 9039862 — intervention group
Group type: COMPARATOR
Intervention: Indoor fungus concentrations in control children
Number of subjects: 92
Study 9039862 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fungus concentrations
Number of subjects: 92
Study 9039862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladosporium and Penicillium concentrations
Number of subjects: 92
Study 9039862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus, Cladosporium, Penicillium, and yeast concentrations
Number of subjects: 92
Study 9039862 — intervention group
Group type: EXPERIMENTAL
Intervention: Home dampness
Number of subjects: 92
Study 9039862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladosporium occurrence
Number of subjects: 92
Study 9039862 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillium concentrations
Number of subjects: 92
Study 7950836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 84
Study 7950836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryotherapy)
Number of subjects: 84
Study 2969910 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 6
Study 2969910 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 6
Study 29034443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary anesthesia (ILA)
Number of subjects: 266
Study 27474888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 0
Study 24796049 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation at the running course of 12 regular meridians and back-shu points in bronchial asthma patients
Number of subjects: 96
Study 24796049 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation at back-shu points
Number of subjects: 96
Study 22585212 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine dosing algorithm based on allometric scaling
Number of subjects: 0